KRAS and non-small cell lung carcinoma: Tao and DeNicola et al. identified enhanced NFE2L2 mRNA levels with constitutive expression of K-RAS(G12D) [154,155] and showed that K-RAS binds to NFE2L2 exon 1 and up-regulates its expression, conferring chemoresistance on NSCLC cells [154].